Hydrochloric Acid → 1-(3-((4-(Ethylsulfonyl)piperazin-1-yl)methyl)-2-fluorophenyl)-3-(2-methylpyridin-4-yl)urea

HRID 539716Notes

Reaction equation

HRID 539716 reaction equation
[F:1][C:2]1[C:21]([NH:22][C:23]([NH:25][C:26]2[CH:31]=[CH:30][N:29]=[C:28]([CH3:32])[CH:27]=2)=[O:24])=[CH:20][CH:19]=[CH:18][C:3]=1[CH2:4][N:5]1[CH2:10][CH2:9][N:8](C(OC(C)(C)C)=O)[CH2:7][CH2:6]1.Cl.CCN(CC)CC.[CH2:41]([S:43](Cl)(=[O:45])=[O:44])[CH3:42]>CO.C(Cl)Cl>[CH2:41]([S:43]([N:8]1[CH2:9][CH2:10][N:5]([CH2:4][C:3]2[C:2]([F:1])=[C:21]([NH:22][C:23]([NH:25][C:26]3[CH:31]=[CH:30][N:29]=[C:28]([CH3:32])[CH:27]=3)=[O:24])[CH:20]=[CH:19][CH:18]=2)[CH2:6][CH2:7]1)(=[O:45])=[O:44])[CH3:42]

Participants

7

Procedure

To a solution of tert-butyl 4-(2-fluoro-3-(3-(2-methylpyridin-4-yl)ureido)benzyl)piperazine-1-carboxylate (600 mg, 1.35 mmol, 1.0 equiv) in MeOH (3 mL) was added HCl (4N in dioxane, 3 mL, 12 mmol, 8.9 equiv). After 1 h, the solvent was removed in vacuo. To this residue was added DCM (10 mL) and Et3N (875 μL, 6.28 mmol, 4.65 equiv), and the resulting solution was divided into two equal parts. To the resulting solution was added ethanesulfonyl chloride (90 μL, 0.95 mmol, 1.4 equiv) dropwise by syringe. After 30 min, the reaction was quenched by the addition of aq. satd. NaHCO3. The reaction was diluted with EtOAc, and washed twice with aq. satd. NaHCO3 and once with brine. The solution was then dried over sodium sulfate, filtered and concentrated in vacuo. Purification by reverse phase preparative HPLC provided 1-(3-((4-(ethylsulfonyl)piperazin-1-yl)methyl)-2-fluorophenyl)-3-(2-methylpyridin-4-yl)urea (267 mg, 90%). LCMS m/z (APCI)=436.2 (M+H).

Workup

  1. customthe solvent was removed in vacuo
  2. waitAfter 30 min
  3. customthe reaction was quenched by the addition of aq. satd
  4. additionThe reaction was diluted with EtOAc
  5. washwashed twice with aq. satd
  6. dry with materialThe solution was then dried over sodium sulfate
  7. filtrationfiltered
  8. concentrationconcentrated in vacuo
  9. customPurification by reverse phase preparative HPLC

Sources & evidence

ORD record
ord-857a063cf3b54cdb9c72ad16c6d7f556
Source dataset
uspto-grants-2014_10
Patent number
US08871768B2

Reaction notes

Loading…